Company news
Wave Life Sciences Ltd. (NASDAQ:WVE) news
Every Wave Life Sciences Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
September 3, 2026
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
August 10, 2026
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
August 5, 2026
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
July 23, 2026
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
July 7, 2026
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometab...
June 24, 2026
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
May 19, 2026
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both...
May 18, 2026
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
Wave Life Sciences : Amendment to Annual Report (Form 10-K/A)
April 30, 2026
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
April 28, 2026
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
April 22, 2026
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
April 21, 2026
Wave Life Sciences Announces Proposed Redomiciliation to the United States
April 15, 2026
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meanin...
March 26, 2026
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American ...
March 5, 2026
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 23, 2026
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
February 19, 2026
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
February 2, 2026
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Developmen...
January 12, 2026
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 9, 2025
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Imp...
December 8, 2025
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 8, 2025
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
December 7, 2025
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
Wave Life Sciences to Present at Upcoming Investor Conferences
November 7, 2025
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
November 4, 2025
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
November 4, 2025
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
October 29, 2025
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity ...
October 29, 2025
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
September 24, 2025
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
September 18, 2025
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
September 3, 2025
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
July 30, 2025
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
July 23, 2025
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle,...
June 20, 2025
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
May 29, 2025
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
May 28, 2025
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
May 1, 2025
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of...
March 26, 2025
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 4, 2025
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
February 25, 2025
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
February 6, 2025
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
January 13, 2025
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
December 23, 2024
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024